Similar articles

• Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism.

  St-Hilaire M, Landry E, Lévesque D, Rouillard C. St-Hilaire M, et al. Neurobiol Dis. 2005 Nov;20(2):450-60. doi: 10.1016/j.nbd.2005.04.001. Neurobiol Dis. 2005. PMID: 15896973
• Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.

  Hossain MA, Weiner N. Hossain MA, et al. J Pharmacol Exp Ther. 1993 Dec;267(3):1105-11. J Pharmacol Exp Ther. 1993. PMID: 8263772
• Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.

  Schneider MB, Murrin LC, Pfeiffer RF, Deupree JD. Schneider MB, et al. Clin Neuropharmacol. 1984;7(3):247-57. Clin Neuropharmacol. 1984. PMID: 6435870
• Levodopa: pharmacology, pharmacokinetics, and pharmacodynamics.

  Juncos JL. Juncos JL. Neurol Clin. 1992 May;10(2):487-509. Neurol Clin. 1992. PMID: 1584186 Review.
• [Action mechanism of L-dopa: dopaminergic activation or glutamatergic inhibition?].

  Vamvakidès A. Vamvakidès A. Ann Pharm Fr. 1993;51(1):8-15. Ann Pharm Fr. 1993. PMID: 8215122 Review. French.